NEWS HIGHLIGHTSMedia Articles Related to Akne-Mycin (Erythromycin Topical)
Pediatricians Endorse New Acne Treatment Guidelines Source: MedicineNet Acne Specialty [2013.05.06] Title: Pediatricians Endorse New Acne Treatment Guidelines Category: Health News Created: 5/6/2013 10:35:00 AM Last Editorial Review: 5/6/2013 12:00:00 AM
Tx for Pediatric Acne Gets New Guidance (CME/CE) Source: MedPage Today Dermatology [2013.05.04] (MedPage Today) -- Typically seen as a teenager's disease, acne also presents in children and infants, and treatments should be age appropriate, according to new recommendations from the American Acne and Rosacea Society.
With Acne, Bacteria Strain on Your Skin May Be Culprit Source: MedicineNet Acne Specialty [2013.02.28] Title: With Acne, Bacteria Strain on Your Skin May Be Culprit Category: Health News Created: 2/28/2013 10:35:00 AM Last Editorial Review: 2/28/2013 12:00:00 AM
Study Finds No Tie Between Acne Drug Accutane and Crohn's, Colitis Source: MedicineNet Acne Specialty [2013.02.21] Title: Study Finds No Tie Between Acne Drug Accutane and Crohn's, Colitis Category: Health News Created: 2/20/2013 4:35:00 PM Last Editorial Review: 2/21/2013 12:00:00 AM
Health Tip: Caring for Acne Source: MedicineNet Acne Specialty [2012.10.10] Title: Health Tip: Caring for Acne Category: Health News Created: 10/10/2012 8:05:00 AM Last Editorial Review: 10/10/2012 12:00:00 AM
Published Studies Related to Akne-Mycin (Erythromycin Topical)
A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. [2011.09.18] Abstract Although erythrasma is a superficial skin infection, there is no consensus on the treatment model of erythrasma... Conclusion: Topical fusidic acid proved to be the most effective treatment; however, clarithromycin therapy may be an alternative regimen in the treatment of erythrasma because of its efficiency and better patient's compliance.
Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne. [2010.12] Topical antibiotics are the mainstay of therapy in mild to moderate inflammatory acne... We conclude that when topically applied, both nadifloxacin 1% cream and erythromycin 4% gel are equally effective and safe treatments for mild to moderate facial acne.
Oral amoxicillin vs. oral erythromycin in the treatment of pyoderma in Bamako, Mali: an open randomized trial. [2007.10] BACKGROUND: Pyoderma (bacterial superficial skin infection) is an extremely common disorder in tropical developing countries. In these settings, Streptococcus pyogenes is considered to be the main etiological agent. Apart from epidemics of poststreptococcal glomerulonephritis where mass treatment with intramuscular benzathine-penicillin is recommended, no recommendation exists for the treatment of pyoderma in this setting. The aim of this study was to evaluate the efficacy of oral amoxicillin in the treatment of pyoderma in Mali, by comparison with oral erythromycin... CONCLUSIONS: Amoxicillin was as efficacious as erythromycin in the treatment of severe pyoderma in Mali. Owing to its efficacy, added to high availability and low cost, this compound should be considered a first-line treatment of this disorder in this country, and perhaps in other countries where this condition presents in a similar way.
A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. [2007.03] CONCLUSIONS: CDP + BPO and ERY + Zn are effective treatments for acne but CDP + BPO has an earlier onset of action that should improve patient compliance.
Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of
mild to moderate acne. [2010] Topical antibiotics are the mainstay of therapy in mild to moderate inflammatory
acne... We conclude that when topically
applied, both nadifloxacin 1% cream and erythromycin 4% gel are equally effective
and safe treatments for mild to moderate facial acne.
Clinical Trials Related to Akne-Mycin (Erythromycin Topical)
Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis [Recruiting]
Erythromycin is effectively used in the treatment of Gastroparesis (GP) patients. In
susceptible patients however, it has been associated with sudden cardiac death due to
prolongation of QT intervals and subsequent cardiac risks through its interaction some other
drugs. Azithromycin (AZI) is a macrolide antibiotic but does not have the mentioned druf
interactions , has fewer gastrointestinal side effects, and fewer risks of QT prolongation
and cardiac arrhythmias. Consequently, AZI avoids drawbacks of dosing with erythromycin and
may be preferred as a prokinetic agent in patients on other concomitant medications.
We hope to demonstrate the effectiveness of Azithromycin (AZI) as compared to Erythromycin
in the treatment of Gastroparesis (GP), and later, form the framework for larger
randomized-controlled parallel studies to investigate use of AZI for treatment of GP.
Our novel hypothesis is to determine whether AZI can be used to treat GP.
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin [Recruiting]
Dowling Meara type of epidermolysis bullosa simplex (EBS-DM) is a rare genodermatosis due to
keratin 5 and 14 mutation, characterized by skin fragility and spontaneous or post traumatic
blisters. Neonatal period and infancy are critical since this autonomic dominant affection
usually improves with age. Cyclins seem to be efficient in some cases of EBS but are
prohibited in children younger than 8 years old. Erythromycin can be a good alternative in
this population due to its antibacterial and anti-inflammatory potential.
The aim of this study is the evaluation of the efficiency of oral erythromycin to decrease
the number of cutaneous blisters in severe EBS-DM patients from 6 months to 8 years old
after 3 months of treatment.
Primary end point is the number of patients with decrease of blisters' number of at least
20% after 3 months of treatment by oral erythromycin.
It is a preliminary study on 8 patients. Treatment is oral erythromycin twice a day during 3
months. Follow up for each patient is 5 months. The duration of the study is 1 year.
A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function [Recruiting]
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of
rivaroxaban when administered with erythromycin to study participants with mild or moderate
renal impairment compared to the pharmacokinetics and pharmacodynamics of rivaroxaban
administered to study participants with normal renal function.
Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients [Recruiting]
42 patients admitted in ICU with intolerance to enteral feeding (GRV more than 250 ml) are
recruited. All patients enter a primary acetaminophen absorption test study as baseline.
Serum levels of acetaminophen will be measured by florescence polarization method at
15,30,45,60,90,120,180,240,480 minutes after enteral administration of 975 mg acetaminophen.
Then the patients will be randomized to methylnaltrexone or erythromycin group. Another
acetaminophen absorption test with the same schedule will be done after the last dose of
each drug. The area under the curve for acetaminophen blood level will be used to compare the
effect of two studied drugs on gastric emptying time.
Neuroprotection With Erythromycin in Cardiac Surgery [Recruiting]
Neurological complications occur in open heart surgery with a frequency of 40% and they
range from major neurological deficits (due to a stroke) to neurocognitive and behavioral
disorders. This study aims to determine if erythromycin, a worldwide known antibiotic,
protects the brain from damage when given in high doses before and during open heart
surgery.
The investigators consume that high dose of erythromycin will protect the brain with a
pharmacological preconditioning against the global ischemia during the perioperative period
of heart surgery.
|